103 related articles for article (PubMed ID: 10594854)
1. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus.
Sarbia M; Bektas N; Müller W; Heep H; Borchard F; Gabbert HE
Cancer; 1999 Dec; 86(12):2597-601. PubMed ID: 10594854
[TBL] [Abstract][Full Text] [Related]
2. Allelic loss involving the tumor suppressor genes APC and MCC and expression of the APC protein in the development of dysplasia and carcinoma in Barrett esophagus.
Bektas N; Donner A; Wirtz C; Heep H; Gabbert HE; Sarbia M
Am J Clin Pathol; 2000 Dec; 114(6):890-5. PubMed ID: 11338478
[TBL] [Abstract][Full Text] [Related]
3. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
4. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
Villanacci V; Bellone G; Battaglia E; Rossi E; Carbone A; Prati A; Verna C; Niola P; Morelli A; Grassini M; Bassotti G
Hum Pathol; 2008 Mar; 39(3):403-9. PubMed ID: 18261624
[TBL] [Abstract][Full Text] [Related]
5. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions.
Geddert H; Zeriouh M; Wolter M; Heise JW; Gabbert HE; Sarbia M
Am J Clin Pathol; 2002 Jul; 118(1):60-6. PubMed ID: 12109857
[TBL] [Abstract][Full Text] [Related]
6. Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus.
Geddert H; Heep HJ; Gabbert HE; Sarbia M
Cancer; 2002 Jan; 94(1):212-8. PubMed ID: 11815979
[TBL] [Abstract][Full Text] [Related]
7. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
[TBL] [Abstract][Full Text] [Related]
8. Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus.
Sarbia M; Arjumand J; Wolter M; Reifenberger G; Heep H; Gabbert HE
Am J Clin Pathol; 2001 Jun; 115(6):835-40. PubMed ID: 11392879
[TBL] [Abstract][Full Text] [Related]
9. Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus.
Hermann B; Li Y; Ray MB; Wo JM; Martin RC
Arch Surg; 2005 Dec; 140(12):1204-9; discussion 1209. PubMed ID: 16365243
[TBL] [Abstract][Full Text] [Related]
10. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
[TBL] [Abstract][Full Text] [Related]
11. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Dorer R; Odze RD
Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
[TBL] [Abstract][Full Text] [Related]
12. Expression of the RB protein, allelic imbalance of the RB gene and amplification of the CDK4 gene in metaplasias, dysplasias and carcinomas in Barrett's oesophagus.
Sarbia M; Tekin U; Zeriouh M; Donner A; Gabbert HE
Anticancer Res; 2001; 21(1A):387-92. PubMed ID: 11299766
[TBL] [Abstract][Full Text] [Related]
13. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
[TBL] [Abstract][Full Text] [Related]
14. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
15. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
16. [Oncogene amplification and genetic heterogeneity in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus].
Walch A; Bink K; Hutzler P; Zitzelsberger H; Braselmann H; Aubele M; Höfler H; Werner M
Verh Dtsch Ges Pathol; 2001; 85():257-63. PubMed ID: 11894407
[TBL] [Abstract][Full Text] [Related]
17. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
18. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma.
Abraham SC; Wang H; Wang KK; Wu TT
Am J Surg Pathol; 2008 Jul; 32(7):1068-74. PubMed ID: 18496141
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development.
Lonardo F; Rusch V; Langenfeld J; Dmitrovsky E; Klimstra DS
Cancer Res; 1999 May; 59(10):2470-6. PubMed ID: 10344760
[TBL] [Abstract][Full Text] [Related]
20. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
